ArticleFrontiers in cardiovascular medicine2026
Plasma metabolic profiling reveals exploratory metabolic differences in chronic coronary syndrome with coronary artery calcification.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/objectives: Coronary artery calcification (CAC) is a specific marker of coronary atherosclerotic heart disease, with chronic coronary syndrome (CCS) being a primary clinical manifestation of coronary artery disease. However, research on the plasma metabolites of individuals with CCS and CAC, as well as the identification of candidate markers is scarce. Here we aimed to explore metabolic differences among CAC patients, CCS patients, and healthy controls. Methods: We conducted a study involving 30 patients with CCS (CCS group), 30 with CAC (CAC group), and 30 healthy controls (Control group). Plasma parameters were statistically analyzed. Moreover, metabolomics analysis explored the composition and functions of metabolites in the plasma of each group. Results: We found that serum creatinine and fasting glucose levels were significantly increased in the CAC group, whereas blood urea nitrogen levels were significantly higher in both the CAC and CCS groups compared with Control group. Significant metabolic differences were observed between the CCS and CAC groups. Further analyses indicated that oleic acid and arachidonic acid were among the metabolites contributing to the separation between CAC patients and healthy controls. Conclusion: These findings suggest that plasma metabolite profiles differ among the study groups. The identified metabolites may contribute to distinguishing CAC patients from those with CCS as well as healthy controls, providing additional insights into the metabolic alterations associated with these conditions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.